Developer docs
API playgroundTry for free, no card

Search company profiles

RenovoDerm

Full company profile

uuid0002xd8

Namestring
RenovoDerm
Legal namestring
RenovoDerm LLC
Websiteurl
renovoderm.tech
Company typeenum
Private
Founded yearint
2016
Descriptiontext

RenovoDerm, LLC is a privately held regenerative medicine company founded in 2016 and headquartered in Dublin, Ohio, that develops and commercializes synthetic wound care devices for the treatment of acute, chronic, and burn wounds. The company's flagship product, Phoenix Wound Matrix, is a 3D electrospun synthetic polymer matrix engineered to mimic native extracellular matrix (ECM) morphology. Unlike allogeneic or xenogeneic skin substitutes, the product is fully synthetic, contains no human or animal tissue, and biodegrades into alpha-hydroxy acids and fatty acids that lower local pH and provide lactate-mediated effects to address wound chronicity and persistent inflammation. The technology platform originates from technical parent Nanofiber Solutions (10+ years of electrospun scaffold development), and RenovoDerm itself operates as a commercial subsidiary under Paragen Technologies, LLC.

The commercial portfolio includes Phoenix Wound Matrix (the primary FDA 510(k)-cleared product), Anthem Wound Matrix (a private-label variant for government channels), and the Rotium Bioresorbable Wick for orthopedic tendon-to-bone repair. Revenue is generated through unit-based sales of the device to healthcare providers, reimbursed under dedicated HCPCS code C1849 as a high-cost skin substitute under the Medicare Outpatient Prospective Payment System. Go-to-market is hybrid: enterprise field sales through independent sales representatives and distributors targeting surgical specialties (Podiatry, Vascular, General, Plastics, Orthopedics, Dermatology) at commercial hospitals, alongside government-channel distribution via Academy Medical's DoD DAPA contract and Regenisource's SDVOSB IDIQ contract for VA and military facilities. As of May 2026, RenovoDerm announced a merger with Atreon Orthopedics to combine synthetic biomaterials platforms across multiple surgical specialties.

Short descriptiontext

RenovoDerm is a private Ohio-based medical device company that develops and commercializes fully synthetic, bioabsorbable 3D electrospun wound matrices — led by the FDA-cleared Phoenix Wound Matrix — for acute, chronic, and burn wounds in commercial hospitals and federal VA/DoD healthcare facilities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersColumbus, United States
HQ citystring
Columbus
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
synthetic wound matrix, electrospun polymer scaffold, skin substitute devices, advanced wound care, regenerative wound healing
Industry2 codes
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Advanced Wound Care Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Phoenix Wound Matrix Sales
TypeOne Time License
Description

Sale of FDA-cleared synthetic wound care devices to healthcare providers and institutions. Product is reimbursed under HCPCS code C1849 as a high-cost skin substitute under Medicare Outpatient Prospective Payment System.

renovoderm.tech
2Anthem Wound Matrix Sales
TypeOne Time License
Description

Private label brand of Phoenix Wound Matrix distributed through Regenisource to government healthcare facilities.

renovoderm.tech
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Pricing details1 tier
1Quote-based pricing for healthcare institutions
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing based on per square centimeter units. Quote-based / Not publicly disclosed.

renovoderm.tech
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Phoenix Wound Matrix
Description

Primary product - a 3D electrospun synthetic polymer matrix for wound healing, designed to mimic extracellular matrix for tissue regeneration of acute and chronic wounds, and burns

renovoderm.tech
+1 more record
Core offering1 text field

RenovoDerm develops, manufactures, and sells advanced wound care products built on proprietary 3D electrospun synthetic polymer matrix technology designed to mimic native extracellular matrix morphology. Its flagship Phoenix Wound Matrix is an FDA 510(k)-cleared, fully synthetic, fully bioabsorbable device for the treatment of acute, chronic, and burn wounds, reimbursed under Medicare HCPCS code C1849 and sold to hospitals, surgeons, and federal (VA/DoD) healthcare facilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • By day 31, wounds were completely re-epithelialized with mature granulation tissue and receding inflammatory response in GLP animal study
+2 more records
Product overview1 text field

RenovoDerm offers a focused portfolio of advanced wound care products centered on its core Phoenix Wound Matrix technology. The flagship Phoenix Wound Matrix is a 3D electrospun synthetic polymer matrix that provides a temporary microenvironment supporting endogenous wound healing. Anthem Wound Matrix is a private-label version of the same core technology distributed through government channels. The company also offers the Rotium Bioresorbable Wick for orthopedic applications. All products leverage electrospun polymer technology designed to mimic the extracellular matrix (ECM) and promote tissue regeneration rather than protracted inflammation.

Product and service2 records
1Phoenix Wound Matrix
CategoryAdvanced Wound Care — Synthetic Skin Substitute
Description

A 3D electrospun synthetic polymer matrix wound care device designed to improve wound healing outcomes by addressing chronicity and persistent inflammation. Fully resorbable, fully synthetic, and contains no human or animal tissue/cells, providing a temporary microenvironment that supports endogenous wound healing and regeneration of native tissue. FDA 510(k) cleared for acute, chronic, and burn wounds; reimbursed under Medicare HCPCS code C1849.

2ANTHEM Wound Matrix
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-20
Description

Merger announcement combining RenovoDerm and Atreon Orthopedics synthetic biomaterials platforms for tissue repair. The merger aims to expand applications and clinical evidence, supporting scalable growth across multiple surgical specialties. Post-merger, RenovoDerm operates as part of the combined entity.

Strategic tierCoreTypeTechnology or Integration
Description

Technical parent company with 10+ years experience in electrospun scaffold technology. Developed the platform technology that created Phoenix Wound Matrix. Nanofiber Solutions designs and manufactures 3D nanofiber scaffolds designed to mimic the extracellular matrix found within the body.

3Paragen Technologies
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Parent company of a family of companies focused on diverse clinical areas including wound care, orthopedics, peripheral vascular, and hernia repair. Ronald Bracken serves as CEO of both Paragen Technologies and its commercial subsidiaries including RenovoDerm.

renovoderm.tech
Strategic tierMinorTypeOthers
Description

Startup nursery partner that believes in unlocking the potential of technology commercialization, bringing disruptive technology to market.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Government contractor providing access to DoD DAPA contract for Phoenix Wound Matrix and Rotium Bioresorbable Wick products. Academy Medical enables access to federal government medical facilities and helps companies navigate government contracting processes.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

SDVOSB (Service-Disabled Veteran-Owned Small Business) providing IDIQ contract access for ANTHEM Wound Matrix distribution to help heal veteran and military wounds. Customer service available at 877-862-5478.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor in skin substitutes and advanced wound care; RenovoDerm's CCO Hilary Dixon previously held senior marketing roles at MiMedx, and both companies compete in the same C1849-reimbursed synthetic/biologic skin substitute category.

TypeEmerging player
Description

Smaller regenerative medicine company developing autologous skin and soft-tissue products; overlaps with RenovoDerm in skin regeneration and wound healing, though with a different (cellular) technology approach.

TypeDirect peer
Description

Direct competitor in skin substitutes and wound healing (e.g., Apligraf, Dermagraft), serving similar chronic wound patient populations and selling through overlapping hospital, VA, and outpatient channels.

TypeBroad incumbent
Description

Established wound and skin care incumbent with a portfolio of advanced dressings; competes with Phoenix in chronic wound management for diabetic foot ulcers, venous leg ulcers, and pressure ulcers.

TypeBroad incumbent
Description

Major wound and ostomy care player (e.g., AQUACEL, InnovaMatrix) with overlapping hospital and government channel presence; competes directly with Phoenix in advanced skin substitute dressings.

TypeEmerging player
Description

Cellular therapy and regenerative medicine company with wound care applications (e.g., Biovance); competes in the same advanced skin substitute space with a placental-tissue-based approach vs. RenovoDerm's fully synthetic matrix.

TypeBroad incumbent
Description

Global wound care and surgical solutions provider (e.g., Mepilex, Mepitel); competes with Phoenix in hospital-based advanced wound care across the same surgical specialties RenovoDerm targets.

TypeBroad incumbent
Description

Broad medical device incumbent with a sizable regenerative tissue/wound care portfolio (e.g., Integra Dermal Regeneration Template) and orthopedic/soft-tissue lines; competes with Phoenix in advanced wound care and with the post-merger Atreon/RenovoDerm platform in tissue repair.

TypeBroad incumbent
Description

Global incumbent in advanced wound management (e.g., PICO, ALLEVYN, OASIS) and orthopedics; competes with Phoenix in hospital wound care and with RenovoDerm's combined tissue-repair platform in surgical applications.

TypeDirect peer
Description

Synthetic biomaterials company in rotator cuff and tendon repair (Rotium); merged with RenovoDerm in 2026 and now shares the same corporate parent (Paragen Technologies), making it the most directly comparable peer for the combined tissue-repair platform.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RenovoDerm

Advanced Wound Care Devicesrenovoderm.tech

RenovoDerm is a private Ohio-based medical device company that develops and commercializes fully synthetic, bioabsorbable 3D electrospun wound matrices — led by the FDA-cleared Phoenix Wound Matrix — for acute, chronic, and burn wounds in commercial hospitals and federal VA/DoD healthcare facilities.

What RenovoDerm does

RenovoDerm, LLC is a privately held regenerative medicine company founded in 2016 and headquartered in Dublin, Ohio, that develops and commercializes synthetic wound care devices for the treatment of acute, chronic, and burn wounds. The company's flagship product, Phoenix Wound Matrix, is a 3D electrospun synthetic polymer matrix engineered to mimic native extracellular matrix (ECM) morphology. Unlike allogeneic or xenogeneic skin substitutes, the product is fully synthetic, contains no human or animal tissue, and biodegrades into alpha-hydroxy acids and fatty acids that lower local pH and provide lactate-mediated effects to address wound chronicity and persistent inflammation. The technology platform originates from technical parent Nanofiber Solutions (10+ years of electrospun scaffold development), and RenovoDerm itself operates as a commercial subsidiary under Paragen Technologies, LLC.

The commercial portfolio includes Phoenix Wound Matrix (the primary FDA 510(k)-cleared product), Anthem Wound Matrix (a private-label variant for government channels), and the Rotium Bioresorbable Wick for orthopedic tendon-to-bone repair. Revenue is generated through unit-based sales of the device to healthcare providers, reimbursed under dedicated HCPCS code C1849 as a high-cost skin substitute under the Medicare Outpatient Prospective Payment System. Go-to-market is hybrid: enterprise field sales through independent sales representatives and distributors targeting surgical specialties (Podiatry, Vascular, General, Plastics, Orthopedics, Dermatology) at commercial hospitals, alongside government-channel distribution via Academy Medical's DoD DAPA contract and Regenisource's SDVOSB IDIQ contract for VA and military facilities. As of May 2026, RenovoDerm announced a merger with Atreon Orthopedics to combine synthetic biomaterials platforms across multiple surgical specialties.

RenovoDerm firmographics

Firmographics
Name
RenovoDerm
Legal name
RenovoDerm LLC
Website
https://renovoderm.tech
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
RenovoDerm is a private Ohio-based medical device company that develops and commercializes fully synthetic, bioabsorbable 3D electrospun wound matrices — led by the FDA-cleared Phoenix Wound Matrix — for acute, chronic, and burn wounds in commercial hospitals and federal VA/DoD healthcare facilities.
Ownership category
akta.pro rank

RenovoDerm industry classification

Industry
Product category
Advanced Wound Care Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Synthetic wound matrix
  • Electrospun polymer scaffold
  • Skin substitute devices
  • Advanced wound care
  • Regenerative wound healing

Where RenovoDerm is headquartered

Location

Headquarters

HQ city
Columbus
HQ country
United States
HQ region
North America

Offices2 records

Markets served

RenovoDerm business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Phoenix Wound Matrix Sales: Sale of FDA-cleared synthetic wound care devices to healthcare providers and institutions. Product is reimbursed under HCPCS code C1849 as a high-cost skin substitute under Medicare Outpatient Prospective Payment System.
  2. Anthem Wound Matrix Sales: Private label brand of Phoenix Wound Matrix distributed through Regenisource to government healthcare facilities.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goQuote-based pricing for healthcare institutions

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

RenovoDerm product offering

Product offering

Core offering

RenovoDerm develops, manufactures, and sells advanced wound care products built on proprietary 3D electrospun synthetic polymer matrix technology designed to mimic native extracellular matrix morphology. Its flagship Phoenix Wound Matrix is an FDA 510(k)-cleared, fully synthetic, fully bioabsorbable device for the treatment of acute, chronic, and burn wounds, reimbursed under Medicare HCPCS code C1849 and sold to hospitals, surgeons, and federal (VA/DoD) healthcare facilities.

Product overview

RenovoDerm offers a focused portfolio of advanced wound care products centered on its core Phoenix Wound Matrix technology. The flagship Phoenix Wound Matrix is a 3D electrospun synthetic polymer matrix that provides a temporary microenvironment supporting endogenous wound healing. Anthem Wound Matrix is a private-label version of the same core technology distributed through government channels. The company also offers the Rotium Bioresorbable Wick for orthopedic applications. All products leverage electrospun polymer technology designed to mimic the extracellular matrix (ECM) and promote tissue regeneration rather than protracted inflammation.

Differentiator

Problem solved

Functional benefit

Brands

  • Phoenix Wound Matrix: Primary product - a 3D electrospun synthetic polymer matrix for wound healing, designed to mimic extracellular matrix for tissue regeneration of acute and chronic wounds, and burns
  • ANTHEM Wound Matrix

Products and services

  • Phoenix Wound Matrix A 3D electrospun synthetic polymer matrix wound care device designed to improve wound healing outcomes by addressing chronicity and persistent inflammation. Fully resorbable, fully synthetic, and contains no human or animal tissue/cells, providing a temporary microenvironment that supports endogenous wound healing and regeneration of native tissue. FDA 510(k) cleared for acute, chronic, and burn wounds; reimbursed under Medicare HCPCS code C1849.
  • ANTHEM Wound Matrix

Quantifiable outcome

  • By day 31, wounds were completely re-epithelialized with mature granulation tissue and receding inflammatory response in GLP animal study
  • +2 more outcomes

Companies that use RenovoDerm

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

RenovoDerm technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

RenovoDerm partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Atreon OrthopedicscoreStrategic or Co-development Partner · 20 May 2026Merger announcement combining RenovoDerm and Atreon Orthopedics synthetic biomaterials platforms for tissue repair. The merger aims to expand applications and clinical evidence, supporting scalable growth across multiple surgical specialties. Post-merger, RenovoDerm operates as part of the combined entity.
  • Nanofiber SolutionscoreTechnology or IntegrationTechnical parent company with 10+ years experience in electrospun scaffold technology. Developed the platform technology that created Phoenix Wound Matrix. Nanofiber Solutions designs and manufactures 3D nanofiber scaffolds designed to mimic the extracellular matrix found within the body.
  • Paragen TechnologiescoreStrategic or Co-development PartnerParent company of a family of companies focused on diverse clinical areas including wound care, orthopedics, peripheral vascular, and hernia repair. Ronald Bracken serves as CEO of both Paragen Technologies and its commercial subsidiaries including RenovoDerm.
  • Ikove Capital (iKove)minorOthersStartup nursery partner that believes in unlocking the potential of technology commercialization, bringing disruptive technology to market.
  • Academy MedicalcoreChannel Partner/ Reseller/ DistributorGovernment contractor providing access to DoD DAPA contract for Phoenix Wound Matrix and Rotium Bioresorbable Wick products. Academy Medical enables access to federal government medical facilities and helps companies navigate government contracting processes.
  • RegenisourcecoreChannel Partner/ Reseller/ DistributorSDVOSB (Service-Disabled Veteran-Owned Small Business) providing IDIQ contract access for ANTHEM Wound Matrix distribution to help heal veteran and military wounds. Customer service available at 877-862-5478.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

RenovoDerm competitors and assessment

Company assessment

Direct peers

  • MiMedx Group: Direct competitor in skin substitutes and advanced wound care; RenovoDerm's CCO Hilary Dixon previously held senior marketing roles at MiMedx, and both companies compete in the same C1849-reimbursed synthetic/biologic skin substitute category.
  • Organogenesis: Direct competitor in skin substitutes and wound healing (e.g., Apligraf, Dermagraft), serving similar chronic wound patient populations and selling through overlapping hospital, VA, and outpatient channels.
  • Atreon Orthopedics: Synthetic biomaterials company in rotator cuff and tendon repair (Rotium); merged with RenovoDerm in 2026 and now shares the same corporate parent (Paragen Technologies), making it the most directly comparable peer for the combined tissue-repair platform.

Emerging players

  • PolarityTE: Smaller regenerative medicine company developing autologous skin and soft-tissue products; overlaps with RenovoDerm in skin regeneration and wound healing, though with a different (cellular) technology approach.
  • Celularity: Cellular therapy and regenerative medicine company with wound care applications (e.g., Biovance); competes in the same advanced skin substitute space with a placental-tissue-based approach vs. RenovoDerm's fully synthetic matrix.

Broad incumbents

  • Coloplast: Established wound and skin care incumbent with a portfolio of advanced dressings; competes with Phoenix in chronic wound management for diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
  • ConvaTec: Major wound and ostomy care player (e.g., AQUACEL, InnovaMatrix) with overlapping hospital and government channel presence; competes directly with Phoenix in advanced skin substitute dressings.
  • Mölnlycke Health Care: Global wound care and surgical solutions provider (e.g., Mepilex, Mepitel); competes with Phoenix in hospital-based advanced wound care across the same surgical specialties RenovoDerm targets.
  • Integra LifeSciences: Broad medical device incumbent with a sizable regenerative tissue/wound care portfolio (e.g., Integra Dermal Regeneration Template) and orthopedic/soft-tissue lines; competes with Phoenix in advanced wound care and with the post-merger Atreon/RenovoDerm platform in tissue repair.
  • Smith+Nephew: Global incumbent in advanced wound management (e.g., PICO, ALLEVYN, OASIS) and orthopedics; competes with Phoenix in hospital wound care and with RenovoDerm's combined tissue-repair platform in surgical applications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

RenovoDerm social profiles

Digital presence

RenovoDerm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RenovoDerm leadership team

Management profile

Number of profiles

Profiles3 records

RenovoDerm funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RenovoDerm M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RenovoDerm

What does RenovoDerm do?

RenovoDerm develops, manufactures, and sells advanced wound care products built on proprietary 3D electrospun synthetic polymer matrix technology designed to mimic native extracellular matrix morphology. Its flagship Phoenix Wound Matrix is an FDA 510(k)-cleared, fully synthetic, fully bioabsorbable device for the treatment of acute, chronic, and burn wounds, reimbursed under Medicare HCPCS code C1849 and sold to hospitals, surgeons, and federal (VA/DoD) healthcare facilities.

Is RenovoDerm a public or private company?

RenovoDerm is a private company. It is classified as corporate owned and is currently operating.

When was RenovoDerm founded?

RenovoDerm was founded in 2016. It employs 1 to 10 people.

Where is RenovoDerm based?

RenovoDerm is headquartered in Columbus, United States, in the North America region.

How does RenovoDerm make money?

Two revenue lines are on record. Phoenix Wound Matrix Sales are the primary driver. The others are anthem Wound Matrix Sales.

Who are RenovoDerm's main competitors?

Direct peers on record are MiMedx Group, Organogenesis and Atreon Orthopedics. Emerging players are PolarityTE and Celularity. Broad incumbents are Coloplast, ConvaTec, Mölnlycke Health Care, Integra LifeSciences and Smith+Nephew.

Does RenovoDerm have an API?

No public API is recorded for RenovoDerm.

What industry is RenovoDerm in?

RenovoDerm's product category is Advanced Wound Care Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Atreon Orthopedics: Merger With RenovoDerm To Expand Synthetic Biomaterials PlatformAtreon Orthopedics announced a merger with RenovoDerm, combining their synthetic biomaterials platforms for tissue repair. The merger aims to expand applications and clinical evidence, supporting scalable growth across multiple surgical specialties.PR NewswireAtreon Orthopedics® and RenovoDerm® Announce MergerAtreon Orthopedics and RenovoDerm merged to form Atreon Orthopedics, combining synthetic biomaterials for tissue repair. The combined company unites Atreon's tendon-to-bone scaffolds with RenovoDerm's wound matrix, aiming to scale across procedures and specialties. The merger accelerates clinical evidence and product development.SecSEC FORM DRenovoDerm, LLC filed a Form D with the SEC for an exempt securities offering under Rule 506(b) with a total offering amount of $2,000,000. The filing indicates that $275,000 has been sold to six investors as of January 25, 2023, with the remainder still available.SecSEC FORM DRenovoDerm, LLC filed a Form D with the SEC on May 17, 2024, announcing an exempt offering of securities under Rule 506(b). The company has sold $250,000 of its total $500,000 target offering to two investors as of the filing date. The offering is intended to last more than one year and involves debt securities.SecSEC FORM DRenovoDerm, LLC filed a Form D with the SEC to announce an exempt securities offering under Rule 506(b) with a total offering amount of $2 million. The filing indicates that $100,000 has been sold to one investor as of January 25, 2023, with the remaining $1.9 million still available for sale.American City Business JournalsSt. Louis bioscience startup Acera files patent infringement lawsuit against RenovoDerm, related companiesSt. Louis bioscience startup Acera Surgical Inc. filed a patent infringement lawsuit against RenovoDerm and related companies in the U.S. District Court for the District of Delaware. The legal action alleges that the defendants infringed on four patents associated with Acera’s nanofiber technology platform.PR NewswireBiotech Company Files Patent Infringement Suit Against RenovoDerm and its Related CompaniesAcera Surgical, Inc. has filed a patent infringement lawsuit against RenovoDerm LLC and its related companies—Nanofiber Solutions LLC, ParaGen Technologies LLC, and Atreon Orthopedics LLC—in the United States District Court for the District of Delaware. The suit targets four patents related to Acera's nanofiber technology platform (U.S. Patent Nos. 10,080,687, 10,617,512, 10,632,288, and 10,682,444), which cover electrospun nanofiber materials for regenerative medical applications. Acera stated it will pursue aggressive legal action to protect its intellectual property and proprietary information.NewswireRenovoDerm Receives FDA Clearance for Proprietary ProductRenovoDerm announced that the U.S. Food and Drug Administration (FDA) has cleared its proprietary product, the Phoenix Wound Matrix, a fully resorbable synthetic graft designed for wound care. The device accelerates healing and tissue regeneration for acute, chronic, and burn wounds based on results from animal studies and veterinary market cases. RenovoDerm is a subsidiary of ParaGen Technologies, which is jointly owned by Nanofiber Solutions and Ikove Venture Partners.